Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Prospective PhaseⅡ Study of Reduced Toxicity Conditioning Consisted of High Dose-Cytarabine, Fludarabine, Cyclophosphamide +/- Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation

Senji Kasahara, MD PhD, Hiroshi Nakamura, MD, Yuto Kaneda, MD, Yoshikazu Ikoma, MD, Eri Takada, MD, Kimihiro Yamaguchi, MD, Yuhei Shibata, MD PhD, Takuro Matsumoto, MDPhD, Nobuhiko Nakamura, MD PhD, Soranobu Ninomiya, MD PhD, Junichi Kitagawa, MD PhD, Hideko Goto, MD PhD, Takeshi Hara, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MD PhD, Masahito Shimizu, MD PhD, Hisashi Tsurumi, MD

Blood (2017) 130 (Supplement 1): 1960.

https://doi.org/10.1182/blood.V130.Suppl_1.1960.1960

Published: 2017

Journal Articles

High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma

Takuro Matsumoto, MD, Nobuhiko Nakamura, MD PhD, Yuhei Shibata, MD, Hiroshi Nakamura, MD, Ryoko Mabuchi, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Naoe Goto, MD PhD, Senji Kasahara, MD PhD, Hideko Goto, MD PhD, Kenji Fukuno, MD PhD, Takeshi Hara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MD PhD, Masami Oyama, MD PhD, Koshiro Saito, MD PhD, Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 4418.

https://doi.org/10.1182/blood.V124.21.4418.4418

Published: 2014

Journal Articles

A Comparison of THP- Cop and CHOP for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Yuhei Shibata, MD, Nobuhiko Nakamura, MD PhD, Senji Kasahara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Yoshikawa, MD PhD, Hiroshi Nakamura, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Naoe Goto, MD PhD, Takeshi Hara, MD PhD, Koshiro Saito, MD PhD, Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 3059.

https://doi.org/10.1182/blood.V124.21.3059.3059

Published: 2014

Journal Articles

A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

Naoe Goto, MD PhD, Takuro Matsumoto, MD, Yuhei Shibata, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Yoshikawa Takeshi, MDPhD, Senji Kasahara, MD PhD, Hideko Goto, MDPhD, Kenji Fukuno, MD, Takeshi Hara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MDPhD, Koshiro Saito, MD PhD, Hisataka Moriwaki, Prof., Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 3078.

https://doi.org/10.1182/blood.V124.21.3078.3078

Published: 2014

Journal Articles

Serum Interleukin-18 Level Determines Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma in Rituximab Era.

Naoe Goto, Hisashi Tsurumi, MD, PhD, Senji Kasahara, Takeshi Hara, Nobuhiro Kanemura, Takeshi Yoshikawa, Soranobu Ninomiya, Kengo Ogawa, Toshiki Yamada, MD, Michio Sawada, Tsuyoshi Takami, Hisataka Moriwaki

Blood (2009) 114 (22): 1926.

https://doi.org/10.1182/blood.V114.22.1926.1926

Published: 2009

Journal Articles

A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

Hisashi Tsurumi, MD, PhD, Naoe Goto, Takeshi Hara, Senji Kasahara, Nobuhiro Kanemura, Junichi Kitagawa, MD, Takeshi Yoshikawa, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Blood (2008) 112 (11): 3599.

https://doi.org/10.1182/blood.V112.11.3599.3599

Published: 2008

Journal Articles

Continuous Drip Infusion of Low Dose Cytrabine and Etoposide with Granulocyte Colony-Stimulating Factor for Elderly Acute Myeloid Leukemia Patients Hardly Tolerable Intensive Chemotherapy - Phase II Study.

Nobuhiro Kanemura, MD, Hisashi Tsurumi, MD, PhD, Takeshi Hara, MD, PhD, Senji Kasahara, MD, PhD, Naoe Goto, MD, Kenji Fukuno, MD, Toshiki Yamada, MD, PhD, Michio Sawada, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2005) 106 (11): 1858.

https://doi.org/10.1182/blood.V106.11.1858.1858

Published: 2005

Journal Articles

Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

Yasushi Kojima, MD, Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Takeshi Hara, MD, PhD, Takeshi Takahashi, MD, PhD, Tetsuya Yamada, MD, PhD, Masanao Saio, MD, PhD, Eiichi Tomita, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 3267.

https://doi.org/10.1182/blood.V104.11.3267.3267

Published: 2004

Journal Articles

Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, Masao Takemura, PhD, Takeshi Hara, MD, PhD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Senji Kasahara, MD, PhD, Nobuhiro Kanemura, MD, Takeshi Takahashi, MD, PhD, Masami Oyama, MD, PhD, Eiichi Tomita, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 3271.

https://doi.org/10.1182/blood.V104.11.3271.3271

Published: 2004

Journal Articles

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Naoe Goto, MD, Hisashi Tsurumi, MD, PhD, Masao Takemura, PhD, Takeshi Hara, MD, PhD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Senji Kasahara, MD, PhD, Nobuhiro Kanemura, MD, Takeshi Takahashi, MD, PhD, Mitsuru Seishima, MD, PhD, Tsuyoshi Takami, MD, PhD, Koshiro Saito, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 4543.

https://doi.org/10.1182/blood.V104.11.4543.4543

Published: 2004

NARROW

Prospective PhaseⅡ Study of Reduced Toxicity Conditioning Consisted of High Dose-Cytarabine, Fludarabine, Cyclophosphamide +/- Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation

High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma

A Comparison of THP- Cop and CHOP for Peripheral T-Cell Lymphoma, Not Otherwise Specified

A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

Serum Interleukin-18 Level Determines Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma in Rituximab Era.

A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

Continuous Drip Infusion of Low Dose Cytrabine and Etoposide with Granulocyte Colony-Stimulating Factor for Elderly Acute Myeloid Leukemia Patients Hardly Tolerable Intensive Chemotherapy - Phase II Study.

Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only